Found: 6
Select item for more details and to access through your institution.
Impact of pain and functional impairment in US adults with haemophilia: Patient‐reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P‐FiQ) study.
- Published in:
- Haemophilia, 2018, v. 24, n. 2, p. 261, doi. 10.1111/hae.13377
- By:
- Publication type:
- Article
Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.
- Published in:
- Haemophilia, 2017, v. 23, n. 4, p. 556, doi. 10.1111/hae.13214
- By:
- Publication type:
- Article
US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry.
- Published in:
- Haemophilia, 2016, v. 22, n. 1, p. e18, doi. 10.1111/hae.12852
- By:
- Publication type:
- Article
Safety of recombinant activated factor VII ( rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg<sup>−1</sup>) rFVIIa doses across clinical trials and registries.
- Published in:
- Haemophilia, 2014, v. 20, n. 1, p. e23, doi. 10.1111/hae.12329
- By:
- Publication type:
- Article
Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
- Published in:
- Haemophilia, 2012, v. 18, n. 6, p. 990, doi. 10.1111/j.1365-2516.2012.02864.x
- By:
- Publication type:
- Article
Patient/Caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
- Published in:
- Haemophilia, 2012, v. 18, n. 3, p. 392, doi. 10.1111/j.1365-2516.2011.02704.x
- By:
- Publication type:
- Article